Annals of Clinical Biochemistry > Volume 46, Number 1 > Pp. 38-43

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: acb.2008.008088v1 46/1/38    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Gu, Y. Articles by Peng, T. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Original Articles

Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases

Yanli Gu¹, Wenli Chen², Yu Zhao¹, Liyun Chen¹ and Tao Peng¹

¹ Laboratory of Viral Immunology, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510663, China; ² Department of Infectious Diseases, Guangdong Provincial People's Hospital, Guangzhou 510080, China

Corresponding author: Dr Tao Peng. Email: peng_tao{at}gibh.ac.cn

Background: Golgi protein-73 (GP73) is a newly identified candidate serum marker for liver diseases. The utility of this biomarker remains limited, largely due to the lack of quantitative information. The aims of this study were to quantify serum GP73 (sGP73) in healthy individuals and in patients with liver diseases, and to validate sGP73 as a biomarker for early diagnosis of liver disease.

Methods: Recombinant GP73 was used to generate monoclonal (mAb) and polyclonal antibodies (pAb). Using these antibodies in a quantitative enzyme-linked immunosorbent assay, GP73 was measured in serum from 263 patients with various forms of liver and other diseases.

Results: The median sGP73 in patients with liver disease was significantly higher (P < 0.001) than in healthy individuals and in patients with other diseases. When sGP73 was used to detect liver disease, it had a sensitivity of 82% and a specificity of 80% at the optimal cut-off value of 85.5 µg/L. The area under the receiver-operating characteristic curve was 0.9.

Conclusion: sGP73 concentration in patients with liver disease was three-fold higher than in healthy individuals. However, sGP73 concentrations did not differ significantly between patients from each liver disease group. Furthermore, sGP73 was not significantly elevated in patients with diseases other than liver disease compared with healthy individuals. These results suggest that sGP73 may be used as a serum marker for the diagnosis of liver disease.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?